|
||
| |||||||
|
Genetix Limited launches QPExpression – new automated bacterial protein expression system New Milton, Hampshire, UK, 14 January 2005 - Genetix Limited has announced the launch of QPExpression - a new system for DNA manipulation that integrates Genetix Limited’s world leading automated colony picking with liquid handling. The system supports the multi-day workflow of plasmid transformations, bacterial streaking, colony imaging, picking, tracking and management. The new system was unveiled at CHI PepTalk in San Diego, USA. QPExpression automates the complete workflow, plating out up to 96 transformation mixes and spreading cells to form single colonies. Following overnight incubation, QPExpression automatically acquires images of the clones derived from each transformation reaction. Using the regional picking software, a user-defined number of colonies from each construct is then picked. Colonies are then dispensed into multiwell plates for QC, sequence verification, protein production or curation. For groups involved with protein supply, expression or structural biology, the use of ligation-independent cloning technologies has become routine practice. However, there is considerable risk of error in these processes because of the need to handle serial reaction steps, multiple clones and Petri dishes. QPExpression mitigates the risk through an integrated system comprising a colony picking instrument that features simple on-board liquid handling and imaging together with the ability to pick and track colonies from 96 separate transformations. Dr Ian Taylor, Business Manager for Genetix, said: “We are very excited to further evolve our core expertise in imaging, high precision picking and data tracking. With our new system we can now automate plating out and spreading of the bacteria. We have already sold and commissioned the first system to a major US Pharmaceutical Company.”About Genetix LimitedGenetix Limited provides automated systems for cell biology, proteomic and genomic research. It supplies many leading academic institutions world-wide and major international companies involved in the drug discovery process including GSK, AstraZeneca and Novartis. Genetix made a significant contribution to the Human Genome Project by supplying high-throughput equipment to seven of the leading eight laboratories of the consortia. Genetix through its R&D expertise and scientific resource is committed to the continual development of innovative solutions to accelerate the rate of global scientific discovery. Genetix is quoted on the London Stock Exchange and is based in New Milton, Hampshire, UK. www.genetix.com www.proteinportfolio.com
Enquiries: Media enquiries Genetix Limited Kapler Communications LtdDr Ian Taylor, Business Manager Richard Kent, Director Tel: +44 (0)1425 624 600 Tel: +44 (0) 1480 471 117 |
|
| ||||||||
